Weekly Anesthesiology Research Analysis
This week’s anesthesiology-related literature emphasized perioperative organ protection, precision therapeutics, and clinically safer anesthesia and analgesia pathways. A multicenter randomized trial found that perioperative dapagliflozin substantially reduced acute kidney injury after elective cardiac surgery, representing the week’s most immediately practice-changing finding. Translational studies identified inflammatory phenotypes that may guide immune therapy in severe pneumonia and showed t
Summary
This week’s anesthesiology-related literature emphasized perioperative organ protection, precision therapeutics, and clinically safer anesthesia and analgesia pathways. A multicenter randomized trial found that perioperative dapagliflozin substantially reduced acute kidney injury after elective cardiac surgery, representing the week’s most immediately practice-changing finding. Translational studies identified inflammatory phenotypes that may guide immune therapy in severe pneumonia and showed that cold-induced adipose thermogenesis can promote venous occlusion through platelet production. Additional randomized studies supported pragmatic advances in regional analgesia, pediatric monitoring, medication-safety tools, and novel sedative or analgesic agents, although several require further validation before routine adoption.
Selected Articles
1. Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
In a multicenter, double-blind randomized trial of 784 adults undergoing elective cardiac surgery, four perioperative doses of dapagliflozin initiated one day before surgery reduced acute kidney injury at seven days from 52% to 28% compared with placebo. The relative risk was 0.54, with nearly complete follow-up and similar rates of atrial fibrillation and reoperation between groups.
Impact: This large, high-quality randomized trial addresses a common and serious perioperative complication for which preventive pharmacotherapy has been lacking. The magnitude of benefit could change kidney-protection strategies in cardiac surgery, although broader safety and generalizability must be confirmed.
Clinical Implications: Perioperative dapagliflozin may become a candidate strategy for preventing acute kidney injury after elective cardiac surgery. Routine adoption should await replication in diverse populations and careful evaluation of volume status, renal function, diabetes, and SGLT2 inhibitor-related risks.
Key Findings
- Among 778 participants with follow-up data, acute kidney injury occurred in 28% with dapagliflozin versus 52% with placebo.
- The relative risk of acute kidney injury was 0.54, with a 95% confidence interval of 0.45 to 0.65.
- Atrial fibrillation and reoperation rates were similar between treatment groups.
2. Cold exposure aggravates vein occlusion through non-shivering thermogenesis-induced thrombocytopoiesis.
This translational study showed that cold exposure increased platelet production through adipose thermogenesis and circulating free fatty acids. Fatty-acid beta-oxidation increased acetyl-CoA, which regulated C/EBPα through p300/SIRT1 and promoted megakaryocyte maturation. Genetic or pharmacological interruption of this pathway reduced deep venous thrombosis and retinal vein occlusion in mice, while human observations showed higher platelet counts during cold exposure and cold seasons.
Impact: The study provides a novel mechanistic explanation for seasonal increases in venous occlusive disease and connects environmental temperature, adipose metabolism, platelet production, and thrombosis. Its cross-species design identifies potentially targetable metabolic pathways, although human causality remains unproven.
Clinical Implications: Cold exposure may be a modifiable environmental risk factor for venous thrombosis in susceptible individuals. The fatty-acid oxidation and p300-related pathways are candidates for future preventive strategies, but no clinical intervention should be based on these findings yet.
Key Findings
- Cold exposure increased platelet counts and aggravated deep venous thrombosis and retinal vein occlusion in mouse models.
- Adipose thermogenesis and fatty-acid beta-oxidation promoted acetyl-CoA-dependent C/EBPα stabilization and platelet production.
- Pathway inhibition reduced cold-induced thrombocytopoiesis and venous occlusion in mice, with supportive seasonal observations in humans.
3. Inflammatory Phenotypes In Severe Pneumonia: Clinical Evidence To Mouse Models For Precision Therapeutics.
Latent class analysis identified hyperinflammatory and hypoinflammatory phenotypes among 548 critically ill patients with pulmonary sepsis. The hyperinflammatory phenotype was associated with greater lung injury and mortality. A pneumococcal pneumonia mouse model reproduced divergent inflammatory trajectories, and dexamethasone or IL-6 receptor blockade benefited only the more inflamed phenotype.
Impact: This study directly links clinically observed inflammatory subgroups to experimentally reproducible biology and differential treatment responses. It addresses a major barrier to precision medicine in pneumonia and sepsis: the failure of uniform immunomodulatory treatment to account for biological heterogeneity.
Clinical Implications: Biomarker-based inflammatory phenotyping may eventually help identify patients who benefit from corticosteroids or IL-6 pathway blockade. Prospective biomarker-stratified trials are needed before phenotype-guided immunomodulation can enter routine practice.
Key Findings
- Two inflammatory phenotypes were identified among 548 patients with pulmonary sepsis, with higher lung injury and mortality in the hyperinflammatory group.
- A pneumococcal pneumonia mouse model reproduced distinct inflammatory trajectories despite uniform pathogen exposure.
- Dexamethasone and IL-6 receptor blockade benefited only the more inflamed experimental phenotype.